Clinical trials: Metabolism Disorder
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
The primary purpose of this Study is to help answer the following research question(s). How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes? How does…
- Trial name
- NCT01215968
- Testing
- LY2189265
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Migraine, Ketogenic Dieting
Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO)
The study aims to investigate the impact of 2 nutritional patterns on high-frequency episodic migraine. Subjects enrolled will be randomized in two arms: a) very-low-calorie-ketogenic-diet (VLCKD), b) hypocaloric balanced non…
- Conditions
- Migraine, Ketogenic Dieting, Weight Loss, Overweight
- Trial name
- EMIKETO (NCT04360148)
- Testing
- very-low-calorie-ketogenic-diet, hypocaloric-balanced-diet
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- New Penta SRL
Type 2 Diabetes
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36 patients from the US will be enrolled in this study.
- Trial name
- NCT00859755
- Testing
- ARRY-403, glucokinase activator; oral
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Array BioPharma
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01326026)
- Testing
- insulin degludec
- Where
- 45 sites in United States, Finland and 2 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device
This clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.
- Trial name
- NCT03352518
- Testing
- WM3.4NR
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- RSP Systems A/S
Mixed Hyperlipidemia
A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia
This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.
- Trial name
- NCT07695597
- Testing
- SYH2070
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Diabetes Mellitus
FreeStyle Libre 3 Continuous Glucose Monitoring System
The purpose of this study is to characterize the FreeStyle Libre 3 Continuous Glucose Monitoring System performance with respect to YSI reference venous plasma sample measurements.
- Trial name
- NCT05962710
- Testing
- FreeStyle Libre 3
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Abbott Diabetes Care
Phenylketonuria
GenSci144 Tablets Phase I Clinical Trial
This study is a Phase I single ascending dose clinical trial in which healthy adult volunteers were administered single oral doses of GenSci144 tablets at different levels.
- Trial name
- NCT07685210
- Testing
- GenSci144 tablets
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Stroke, Ischemic, Stroke Hemorrhagic
Transnasal Induction of Normothermia for Neurogenic Fever
The objective of this study is to evaluate the efficacy of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Seizures, Metabolic Encephalopathy
- Trial name
- NCT06038513
- Testing
- Transnasal Thermal Regulating Device
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- CoolTech LLC
Gout, Acute Gout Flare
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and…
- Conditions
- Gout, Acute Gout Flare, Gout Flares
- Trial name
- ABP-745 (NCT06258213)
- Testing
- ABP-745
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atom Therapeutics Co., Ltd
Malnutrition
Safety and Efficacy of Longterm HPN With Two Lipid Emulsions
It is the purpose of this trial to provide evidence for safety and efficacy of long term home parenteral nutrition with either Lipofundin MCT or Lipoplus in patients with proven insufficient enteral resorption.
- Trial name
- NCT00530738
- Testing
- Lipoplus, Lipofundin MCT
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- B. Braun Melsungen AG
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Iron Deficiency Anemia
Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy
The main purpose is to determine whether FPC, administered via infusion, is safe and effective for the treatment of iron deficiency anemia (IDA) in patients receiving Home Infusion therapies (HI).
- Trial name
- NCT05110768
- Testing
- Triferic AVNU
- Volunteers
- 75 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Trial name
- AURORA-2 (NCT07743450)
- Testing
- ASC30 tablets A1
- Where
- 135 sites in United States, Czechia and 4 more
- Volunteers
- 1,560 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Type 1 Diabetes Mellitus
Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)
Primary Objective: To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
- Trial name
- NCT03260868
- Testing
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Where
- 6 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Sanofi
Hypercholesterolemia
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Primary Objective: To provide participants with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to…
- Trial name
- NCT02476006
- Testing
- ALIROCUMAB SAR236553 (REGN727), ezetimibe, atorvastatin
- Where
- 153 sites in Austria, Belgium and 14 more
- Volunteers
- 998 people
- Sponsor
- Sanofi
Trauma, Hemorrhagic Shock
Phase 2c Dose Comparison Study of MP4OX in Trauma
MP4OX is being developed as an ischemic rescue therapy to perfuse and oxygenate tissues at risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid designed to improve perfusion and target delivery of oxygen…
- Conditions
- Trauma, Hemorrhagic Shock, Lactic Acidosis
- Trial name
- NCT01973504
- Testing
- MP4OX, Control
- Where
- 31 sites in Australia, Belgium and 9 more
- Sponsor
- Sangart
Type 2 Diabetes Mellitus
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.
- Trial name
- NCT01512849
- Testing
- TA-7284 Low, TA-7284 High
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes
A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours
The goal of this clinical research study is to learn about a new minimally invasive glucose monitoring device called Fluorescence Affinity Sensor (FAS).
- Trial name
- FAS (NCT01065948)
- Testing
- Subcutaneous glucose monitoring device
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- BioTex, Inc.